RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
XSpray Pharma AB (publ) Stock

XSpray Pharma AB (publ) Stocks 2025

XSpray Pharma AB (publ) Stocks

26.91 M

Ticker

XSPRAY.ST

ISIN

SE0009973563

WKN

A2H48J

In 2025, XSpray Pharma AB (publ) had 26.91 M outstanding stocks, a 0% change from the 26.91 M stocks in the previous year.

The XSpray Pharma AB (publ) Stocks history

YEARNUMBER OF STOCKS (undefined SEK)
2028e26.91
2027e26.91
2026e26.91
2025e26.91
2024e26.91
202326.91
202221.52
202119.65
202017.37
201915.22
201813.59
20177.95
201612.36
201512.36

XSpray Pharma AB (publ) shares outstanding

The number of shares was XSpray Pharma AB (publ) in 2024 — This indicates how many shares 26.913 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue XSpray Pharma AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates XSpray Pharma AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of XSpray Pharma AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating XSpray Pharma AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

XSpray Pharma AB (publ) Aktienanalyse

What does XSpray Pharma AB (publ) do?

XSpray Pharma AB (publ) was founded in Sweden in 2003 and is headquartered in Stockholm. The company specializes in the development and manufacturing of pharmaceutical products tailored to the needs of patients with unique medical challenges. The business model of XSpray Pharma is based on patenting and selling its MicroSpray technology platform, which allows drugs to be transformed into a microfine spray form, thereby improving bioavailability, duration, and intensity of action. The company has three main divisions: - The first division is contract research, where XSpray Pharma licenses its technology platform to other pharmaceutical companies and assists them in drug development. - The second division is the development of its own medications, where XSpray Pharma develops innovative therapies for rare diseases. The company works closely with patient organizations, doctors, and scientists to better understand patient needs and address their medical challenges. - The third division is partnership with other pharmaceutical companies, where XSpray Pharma contributes its technology platform and drug development expertise to collaboratively develop and market innovative therapies. One of XSpray Pharma's key products is APT-1011, a spray for severe nausea and vomiting in cancer patients that acts quickly and effectively due to its microfine nature. It has received European approval (EMA) and is being submitted in the US in collaboration with US pharmaceutical company RedHill Biopharma. Another important product is APT-1026, a spray for the treatment of hypersensitivity reactions. It is currently in development and is intended to help patients with various types of hypersensitivity reactions in the future. In addition, XSpray Pharma has several patented technology platforms and a wide range of drug candidates in the pipeline. The company works closely with its partners to leverage its technology and expertise in drug development to jointly create innovative therapies for patients. In recent years, XSpray Pharma has received several awards and recognitions for its innovative technology and drug development, including the Swedish Pharma Prize and the European Mediscience Award. In summary, XSpray Pharma is an innovative pharmaceutical company specializing in the development of drugs for patients with unique medical challenges. The company has utilized its MicroSpray technology platform and drug development expertise to develop a wide range of drug candidates in the pipeline aimed at improving the lives of patients. XSpray Pharma AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating XSpray Pharma AB (publ)'s Shares Outstanding

XSpray Pharma AB (publ)'s shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in XSpray Pharma AB (publ)’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding XSpray Pharma AB (publ)’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in XSpray Pharma AB (publ)’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about XSpray Pharma AB (publ) stock

How many stocks are there of XSpray Pharma AB (publ)?

The current number of stocks of XSpray Pharma AB (publ) is 26.91 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of XSpray Pharma AB (publ) are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of XSpray Pharma AB (publ) evolved in recent years?

The number of shares of XSpray Pharma AB (publ) has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. XSpray Pharma AB (publ) as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of XSpray Pharma AB (publ)?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does XSpray Pharma AB (publ) pay?

Over the past 12 months, XSpray Pharma AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, XSpray Pharma AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of XSpray Pharma AB (publ)?

The current dividend yield of XSpray Pharma AB (publ) is .

When does XSpray Pharma AB (publ) pay dividends?

XSpray Pharma AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of XSpray Pharma AB (publ)?

XSpray Pharma AB (publ) paid dividends every year for the past 0 years.

What is the dividend of XSpray Pharma AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is XSpray Pharma AB (publ) located?

XSpray Pharma AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von XSpray Pharma AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of XSpray Pharma AB (publ) from 1/8/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did XSpray Pharma AB (publ) pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of XSpray Pharma AB (publ) in the year 2024?

In the year 2024, XSpray Pharma AB (publ) distributed 0 SEK as dividends.

In which currency does XSpray Pharma AB (publ) pay out the dividend?

The dividends of XSpray Pharma AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von XSpray Pharma AB (publ)

Our stock analysis for XSpray Pharma AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of XSpray Pharma AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.